NAOV NANOVIBRONIX INC Delisting Actions 8-K Filing 2025 - Nasdaq Compliance NanoVibronix Inc announced the completion of the first phase of a randomized control trial for its UroShield device and received a limited extension from Nasdaq to comply with listing requirements, including a reverse stock split by February 27, 2025.Get access to all SEC 8-K filings of the NANOVIBRONIX INC